Ubs Asset Management Americas Inc Cyma Bay Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

$277 Billion
Q1 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $122,713 - $237,750	9,716 Added 12.76%	85,842 $2.03 Million
Q3 2023 Nov 13, 2023	BUY	$10.86 - $17.62 $77,008 - $124,943	7,091 Added 10.27%	76,126 $1.14 Million
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $405,925 - $662,045	69,035 New	69,035 $601,000
Q2 2021 Aug 16, 2021	SELL	$3.94 - $4.92 $431,906 - $539,335	-109,621 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$4.23 - $6.55 $102,327 - $158,451	24,191 Added 28.32%	109,621 $497,000

Q4 2020 Mar 01, 2021	BUY	$5.73 - $9.03 $489,513 - $771,432	85,430 New	85,430 $490,000
Q2 2020 Aug 14, 2020	SELL	$1.41 - $4.25 $154,361 - $465,273	-109,476 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.25 - $2.02 $55,656 - $89,940	44,525 Added 68.55%	109,476 $162,000
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $7,545 - $33,640	-5,673 Reduced 8.03%	64,951 $127,000
Q3 2019 Nov 14, 2019	BUY	$5.12 - $7.21 $20,971 - $29,532	4,096 Added 6.16%	70,624 $361,000
Q2 2019 Aug 15, 2019	SELL	$6.05 - $13.66 $3.05 Million - $6.89 Million	-504,181 Reduced 88.34%	66,528 $0
Q1 2019 May 14, 2019	BUY	$8.16 - $13.42 $287,419 - $472,692	35,223 Added 6.58%	570,709 $0
Q4 2018 Feb 13, 2019	SELL	$6.54 - $11.74 $331,898 - $595,793	-50,749 Reduced 8.66%	535,486 $4.21 Million
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.52 $195,285 - $260,619	17,949 Added 3.16%	586,235 $0
Q2 2018 Aug 14, 2018	SELL	$10.66 - $14.38 $265,753 - $358,493	-24,930 Reduced 4.2%	568,286 $0
Q1 2018 May 14, 2018	BUY	$9.0 - $15.16 $33,534 - $56,486	3,726 Added 0.63%	593,216 $0
Q4 2017 Feb 09, 2018	BUY	$7.67 - $9.31 $4.52 Million - $5.49 Million	589,490	589,490 $0

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.88M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account